Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 574-600, 2006. First published February 23, 2006; 10.1373/clinchem.2005.063040
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.063040v1
52/4/574    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (15)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wopereis, S.
Right arrow Articles by Wevers, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wopereis, S.
Right arrow Articles by Wevers, R. A.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2006;52:574-600.)
© 2006 American Association for Clinical Chemistry, Inc.

Reviews

Mechanisms in Protein O-Glycan Biosynthesis and Clinical and Molecular Aspects of Protein O-Glycan Biosynthesis Defects: A Review

Suzan Wopereis1, Dirk J. Lefeber1, Éva Morava2 and Ron A. Wevers1,a

1 Laboratory of Pediatrics and Neurology and2 Department of Pediatrics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.

aAddress correspondence to this author at: Laboratory of Pediatrics and Neurology (830), Institute of Neurology, Radboud University Nijmegen Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands. Fax 31-24-3540297; e-mail r.wevers{at}cukz.umcn.nl.

Background: Genetic diseases that affect the biosynthesis of protein O-glycans are a rapidly growing group of disorders. Because this group of disorders does not have a collective name, it is difficult to get an overview of O-glycosylation in relation to human health and disease. Many patients with an unsolved defect in N-glycosylation are found to have an abnormal O-glycosylation as well. It is becoming increasingly evident that the primary defect of these disorders is not necessarily localized in one of the glycan-specific transferases, but can likewise be found in the biosynthesis of nucleotide sugars, their transport to the endoplasmic reticulum (ER)/Golgi, and in Golgi trafficking. Already, disorders in O-glycan biosynthesis form a substantial group of genetic diseases. In view of the number of genes involved in O-glycosylation processes and the increasing scientific interest in congenital disorders of glycosylation, it is expected that the number of identified diseases in this group will grow rapidly over the coming years.

Content: We first discuss the biosynthesis of protein O-glycans from their building blocks to their secretion from the Golgi. Subsequently, we review 24 different genetic disorders in O-glycosylation and 10 different genetic disorders that affect both N- and O-glycosylation. The key clinical, metabolic, chemical, diagnostic, and genetic features are described. Additionally, we describe methods that can be used in clinical laboratory screening for protein O-glycosylation biosynthesis defects and their pitfalls. Finally, we introduce existing methods that might be useful for unraveling O-glycosylation defects in the future.




The following articles in journals at HighWire Press have cited this article:


Home page
 ScienceHome page
S. T. Laughlin, J. M. Baskin, S. L. Amacher, and C. R. Bertozzi
In Vivo Imaging of Membrane-Associated Glycans in Developing Zebrafish
Science, May 2, 2008; 320(5876): 664 - 667.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Velayos-Baeza, C. Toma, S. Paracchini, and A. P. Monaco
The dyslexia-associated gene KIAA0319 encodes highly N- and O-glycosylated plasma membrane and secreted isoforms
Hum. Mol. Genet., March 15, 2008; 17(6): 859 - 871.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. C. Harper, A. C. Theos, K. E. Herman, D. Tenza, G. Raposo, and M. S. Marks
Premelanosome Amyloid-like Fibrils Are Composed of Only Golgi-processed Forms of Pmel17 That Have Been Proteolytically Processed in Endosomes
J. Biol. Chem., January 25, 2008; 283(4): 2307 - 2322.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
M. J. Nijland, N. E. Schlabritz-Loutsevitch, G. B. Hubbard, P. W. Nathanielsz, and L. A. Cox
Non-human primate fetal kidney transcriptome analysis indicates mammalian target of rapamycin (mTOR) is a central nutrient-responsive pathway
J. Physiol., March 15, 2007; 579(3): 643 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Wopereis, S. Grunewald, K. M.L.C. Huijben, E. Morava, R. Mollicone, B. G.M. van Engelen, D. J. Lefeber, and R. A. Wevers
Transferrin and Apolipoprotein C-III Isofocusing Are Complementary in the Diagnosis of N- and O-Glycan Biosynthesis Defects
Clin. Chem., February 1, 2007; 53(2): 180 - 187.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. V. Cabrera, M. Amano, J. Mitoma, J. Chan, J. Said, M. Fukuda, and L. G. Baum
Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death
Blood, October 1, 2006; 108(7): 2399 - 2406.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.